ReviewTuberculosis and respiratory diseases2020
Current Status of Immunotherapy for Lung Cancer and Future Perspectives.
Review in Tuberculosis and respiratory diseases, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
- Serial KL-6 Changes in PD-1/PD-L1 Inhibitor-Related Pneumonitis in Non-small Cell Lung Cancer: A Single-Center Prospective Pilot Study.Tuberculosis and respiratory diseases · 2026Article
- Enhancing the Detection of Long-Chain Aldehydes by Peptide-Based Biosensors Through Counter-Ion Exchange.Biosensors · 2026Article
- The Role of Immunotherapy in Lung Cancer Treatment: Current Strategies, Future Directions, and Insights into Metastasis and Immune Microenvironment.Current gene therapy · 2025Review
- The association between clinical parameters and resectability in stage III non-small cell lung cancer, and a combination of N2 lymph node burden and lung immune prognostic index score as a potential biomarker.Translational lung cancer research · 2023Article
- New Targeted Therapy for Non-Small Cell Lung Cancer.Tuberculosis and respiratory diseases · 2023Article
- Novel Biomarkers in Lung Cancer and Chronic Lung Diseases: From the Systematic Perspective ofJournal of clinical medicine · 2022Article
- Characterization of Necroptosis-Related Molecular Subtypes and Therapeutic Response in Lung Adenocarcinoma.Frontiers in genetics · 2022Article
- NEIL3 Mediates Lung Cancer Progression and Modulates PI3K/AKT/mTOR Signaling: A Potential Therapeutic Target.International journal of genomics · 2022Article
- Prognostic characterization of immune molecular subtypes in non-small cell lung cancer to immunotherapy.BMC pulmonary medicine · 2021Article
- Recent Trends of Lung Cancer in Korea.Tuberculosis and respiratory diseases · 2021Article
- Treatment outcomes and safety of afatinib in advanced squamous cell lung cancer progressed after platinum-based doublet chemotherapy and immunotherapy (SPACE study).Thoracic cancer · 2021Article
- Characteristics of the Immune Cell Infiltration Landscape in Gastric Cancer to Assistant Immunotherapy.Frontiers in genetics · 2021Article
- Overexpression of Reactive Oxygen Species Modulator 1 Predicts Unfavorable Clinical Outcome in EGFR-Mutant Lung Adenocarcinomas Treated With Targeted Therapy.Frontiers in oncology · 2021Article
- Acute myelomonocytic leukemia during pembrolizumab treatment for non-small cell lung cancer: A case report.World journal of clinical cases · 2020Article
- Primary Resistance to Immune Checkpoint Blockade in anOncoTargets and therapy · 2020Article
- High PD-L1 Expression is Associated with Unfavorable Clinical Outcome inOncoTargets and therapy · 2020Article
- Diagnostic and Predictive Values ofCancer management and research · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lung cancer remains the most common cause of cancer-related deaths worldwide. Although there are many possible treatments, including targeted therapies such as epidermal growth factor receptor tyrosine kinase inhibitors and anaplastic lymphoma kinase inhibitors, new therapeutic strategies are needed to improve clinical outcomes. Immunotherapy through the use of immune checkpoint inhibitors has provided one of the most important breakthroughs in the management of solid tumors, including lung cancers, and has shown promising results in numerous clinical trials. This review will present the current status of immunotherapy for lung cancer and future perspectives on these treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.